Lenacapavir for pre-exposure prophylaxis (PrEP) has been added to the interaction checker and is available on the website and iChart app. Lenacapavir for PrEP was approved by the FDA in America in June 2025 and was authorized by the European Medicines Agency (EMA) in August 2025. Lenacapavir for PrEP is marketed as Yeztugo® in America and as Yeytuo® in Europe (lenacapavir for antiretroviral treatment is marketed as Sunlenca®).
One area in which the product labels for Yeztugo and Yeytuo differ is in their recommendations regarding coadministration with strong or moderate CYP3A inducers. The Yeztugo American label advises supplemental doses of lenacapavir when initiating strong or moderate CYP3A inducers, whereas the Yeytuo European label states that concomitant administration is contraindicated.
The American and European product labels can be found in the links below:
Yeztugo American Prescribing Information
Yeytuo European Summary of Product Characteristics
